Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment
Source abstract
Abstract
Immunotherapy that harnesses the human immune system to fight cancer has received widespread attention and become a mainstream strategy for cancer treatment. Cancer immunotherapy not only eliminates primary tumors but also treats metastasis and recurrence, representing a major advantage over traditional cancer treatments. Recently with the development of nanotechnology, there exists much work applying nanomaterials to cancer immunotherapy on the basis of their excellent physiochemical properties, such as efficient tissue-specific delivery function, huge specific surface area, and controllable surface chemistry. Consequently, nanotechnology holds significant potential in improving the efficacy of cancer immunotherapy. Nanotechnology-based immunotherapy mainly manifests its inhibitory effect on tumors via two different approaches: one is to produce an effective anti-tumor immune response during tumorigenesis, and the other is to enhance tumor immune defense ability by modulating the immune suppression mechanism in the tumor microenvironment. With the success of tumor immunotherapy, understanding the interaction between the immune system and smart nanomedicine has provided vigorous vitality for the development of cancer treatment. This review highlights the application, progress, and prospect of nanomedicine in the process of tumor immunoediting and also discusses several engineering methods to improve the efficiency of tumor treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmaceutical Sciences, Shandong University, 44 WenhuaXilu, Jinan 250012, China
Funding
Ministry of Science and Technology of the People's Republic of China · Natural Science Foundation of Shandong Province · Shandong Provincial Major Science &Technology Innovation Project
References (100+)
Show source-provided references
1. 10.1038/s41563-018-0091-810.1038/s41563-018-0091-8 ↗
2. 10.1634/theoncologist.2019-023310.1634/theoncologist.2019-0233 ↗
3. 10.1039/C9CS00271E10.1039/C9CS00271E ↗
4. 10.1038/s41423-020-0470-310.1038/s41423-020-0470-3 ↗
5. 10.1038/s41375-020-0930-x10.1038/s41375-020-0930-x ↗
6. 10.1002/advs.20180184710.1002/advs.201801847 ↗
7. 10.1038/s41572-020-0160-610.1038/s41572-020-0160-6 ↗
8. 10.1038/s41467-017-02696-610.1038/s41467-017-02696-6 ↗
9. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
10. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
11. 10.1038/nrc325810.1038/nrc3258 ↗
12. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
13. 10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
14. 10.1038/ni1102-99110.1038/ni1102-991 ↗
15. 10.1126/science.120348610.1126/science.1203486 ↗
16. 10.1016/j.immuni.2013.07.00510.1016/j.immuni.2013.07.005 ↗
17. 10.1038/s41571-018-0142-810.1038/s41571-018-0142-8 ↗
18. 10.1039/C8CS00473K10.1039/C8CS00473K ↗
19. 10.1136/esmoopen-2016-00005610.1136/esmoopen-2016-000056 ↗
20. 10.1002/wnan.161210.1002/wnan.1612 ↗
21. 10.1007/s40005-018-0399-z10.1007/s40005-018-0399-z ↗
22. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
23. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
24. 10.1242/jcs.11639210.1242/jcs.116392 ↗
25. 10.1016/S0140-6736(00)04046-010.1016/S0140-6736(00)04046-0 ↗
26. 10.1016/j.coi.2013.02.00910.1016/j.coi.2013.02.009 ↗
27. 10.1038/s41563-018-0147-910.1038/s41563-018-0147-9 ↗
28. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
29. 10.1002/adma.20180332210.1002/adma.201803322 ↗
30. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
31. 10.1021/nn506202910.1021/nn5062029 ↗
32. 10.1016/j.nantod.2014.10.00110.1016/j.nantod.2014.10.001 ↗
33. 10.1002/anie.20180488210.1002/anie.201804882 ↗
34. 10.18632/oncotarget.226610.18632/oncotarget.2266 ↗
35. 10.1016/j.nantod.2020.10092410.1016/j.nantod.2020.100924 ↗
36. 10.1002/adma.20170558110.1002/adma.201705581 ↗
37. 10.1002/ijc.2807010.1002/ijc.28070 ↗
38. 10.1038/s41577-019-0269-610.1038/s41577-019-0269-6 ↗
39. 10.1016/j.radonc.2019.07.02910.1016/j.radonc.2019.07.029 ↗
40. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
41. 10.1002/adma.20140299610.1002/adma.201402996 ↗
42. 10.1016/j.semcancer.2019.11.01010.1016/j.semcancer.2019.11.010 ↗
43. 10.1016/j.biomaterials.2020.11982710.1016/j.biomaterials.2020.119827 ↗
44. 10.1021/acsnano.9b0604010.1021/acsnano.9b06040 ↗
45. 10.18632/oncotarget.972510.18632/oncotarget.9725 ↗
46. 10.1002/adma.20190092710.1002/adma.201900927 ↗
47. 10.1021/acs.nanolett.9b0521010.1021/acs.nanolett.9b05210 ↗
48. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
49. 10.1016/j.biomaterials.2020.12063810.1016/j.biomaterials.2020.120638 ↗
50. 10.1002/anie.20210270310.1002/anie.202102703 ↗
51. 10.1016/j.bcp.2021.11448710.1016/j.bcp.2021.114487 ↗
52. 10.1039/D0NR05953F10.1039/D0NR05953F ↗
53. 10.1021/jacs.8b1004710.1021/jacs.8b10047 ↗
54. 10.1126/sciadv.aaz208310.1126/sciadv.aaz2083 ↗
55. 10.1021/acs.nanolett.9b0014510.1021/acs.nanolett.9b00145 ↗
56. 10.1016/j.lfs.2020.11755010.1016/j.lfs.2020.117550 ↗
57. 10.1016/j.pharmthera.2019.10745310.1016/j.pharmthera.2019.107453 ↗
58. 10.1016/j.immuni.2019.07.00310.1016/j.immuni.2019.07.003 ↗
59. 10.1002/adhm.20120026810.1002/adhm.201200268 ↗
60. 10.1021/acsnano.8b0589310.1021/acsnano.8b05893 ↗
61. 10.1016/j.jconrel.2018.09.00910.1016/j.jconrel.2018.09.009 ↗
62. 10.1038/nmat377510.1038/nmat3775 ↗
63. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
64. 10.1016/j.ccell.2017.02.00810.1016/j.ccell.2017.02.008 ↗
65. 10.1016/j.nantod.2015.06.00710.1016/j.nantod.2015.06.007 ↗
66. 10.1007/978-1-62703-496-8_210.1007/978-1-62703-496-8_2 ↗
67. 10.1016/j.jconrel.2017.04.02610.1016/j.jconrel.2017.04.026 ↗
68. 10.1158/2326-6066.CIR-14-0019-T10.1158/2326-6066.CIR-14-0019-T ↗
69. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
70. 10.1038/nbt133210.1038/nbt1332 ↗
71. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
72. 10.1016/j.biomaterials.2020.11992810.1016/j.biomaterials.2020.119928 ↗
73. 10.1038/s41563-020-0793-610.1038/s41563-020-0793-6 ↗
74. 10.1038/ni.160110.1038/ni.1601 ↗
75. 10.2174/15672011179525619210.2174/156720111795256192 ↗
76. 10.1016/j.lfs.2020.11876110.1016/j.lfs.2020.118761 ↗
77. 10.1016/j.biomaterials.2019.03.03710.1016/j.biomaterials.2019.03.037 ↗
78. 10.1038/nnano.2011.15310.1038/nnano.2011.153 ↗
79. 10.1038/s41563-018-0256-510.1038/s41563-018-0256-5 ↗
80. 10.1016/j.ccell.2015.03.00110.1016/j.ccell.2015.03.001 ↗
81. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
82. 10.1200/JCO.2016.67.346710.1200/JCO.2016.67.3467 ↗
83. 10.1038/nrclinonc.2015.17010.1038/nrclinonc.2015.170 ↗
84. 10.1056/NEJMoa150764310.1056/NEJMoa1507643 ↗
85. 10.1038/bjc.2014.34810.1038/bjc.2014.348 ↗
86. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
87. 10.1016/j.jconrel.2020.03.05010.1016/j.jconrel.2020.03.050 ↗
88. 10.1016/j.jconrel.2016.01.04410.1016/j.jconrel.2016.01.044 ↗
89. 10.1016/j.biomaterials.2019.11949010.1016/j.biomaterials.2019.119490 ↗
90. 10.1016/j.jconrel.2020.05.03910.1016/j.jconrel.2020.05.039 ↗
91. 10.1016/j.jconrel.2019.06.03110.1016/j.jconrel.2019.06.031 ↗
92. 10.1016/j.biomaterials.2017.11.04810.1016/j.biomaterials.2017.11.048 ↗
93. 10.1016/j.tibtech.2014.06.00710.1016/j.tibtech.2014.06.007 ↗
94. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
95. 10.1021/acs.nanolett.7b0373410.1021/acs.nanolett.7b03734 ↗
96. 10.1038/nbt.404710.1038/nbt.4047 ↗
97. 10.1021/acsnano.7b0495510.1021/acsnano.7b04955 ↗
98. 10.1007/s00262-016-1910-x10.1007/s00262-016-1910-x ↗
99. 10.1016/j.immuni.2018.09.02410.1016/j.immuni.2018.09.024 ↗
100. 10.1038/s41565-020-00822-y10.1038/s41565-020-00822-y ↗